Supartz Side Effects

Generic name: sodium hyaluronate

Note: This document contains side effect information about sodium hyaluronate. Some of the dosage forms listed on this page may not apply to the brand name Supartz.

Some side effects of Supartz may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to sodium hyaluronate: intra-articular solution

Get emergency medical help if you have any of these signs of an allergic reaction while taking sodium hyaluronate (the active ingredient contained in Supartz) hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

• severe pain or swelling around the knee after the injection;

• fast heart rate, sweating, chills or shaking; or

• heavy feeling, anxiety, confusion.

Less serious side effects of sodium hyaluronate may include:

• warmth, pain, stiffness, swelling, or puffiness where the medicine was injected;

• nausea, stomach pain;

• headache;

• back pain;

• numbness or tingly feeling;

• cold symptoms such as stuffy nose, sneezing, sore throat;

• tired feeling; or

• itching or skin irritation around the knee.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to sodium hyaluronate: intra-articular solution

General

Most side effects are related to local reactions such as injection site pain, pain, swelling, effusion, or redness of the joint.

Increased risk, severity, or frequency of side effects does not appear to occur with retreatment of sodium hyaluronate (the active ingredient contained in Supartz)

Local

Local side effects for sodium hyaluronate (the active ingredient contained in Supartz) in relation to placebo therapy have included injection site pain (23% vs 13%), joint pain and swelling (13% vs 13%), and local skin reactions consisting of ecchymosis and rash (14% vs 10%) and pruritus (7% vs 4%). Warmth and redness have also been reported.

Injection site pain was listed as the reason for premature discontinuation of treatment in 4% (6/164) of the patients treated with sodium hyaluronate as compared to < 1% (1/164) of placebo-treated patients.

Patients with inflammatory arthritis may experience transient increases in inflammation of the injected knee following treatment.

Hypersensitivity

Hypersensitivity reactions have included 2 cases of anaphylactoid reactions and 3 cases of allergic reactions, which resolved upon discontinuation of sodium hyaluronate (the active ingredient contained in Supartz)

Hypersensitivity side effects have included anaphylactoid reactions and allergic reactions.

Other

Seven cases of fever were reported in one pivotal clinical study. Subsequently, 3 of these cases were reported to be associated with local reactions. No association to pyrogenic arthritis was found.

Other side effects have included fever and headache.

Gastrointestinal

Gastrointestinal side effects for sodium hyaluronate (the active ingredient contained in Supartz) in relation to placebo therapy have included unspecified complaints (29% vs 36%).

Non-specific gastrointestinal complaints were severe in both 4% of patients treated with sodium hyaluronate and 4% of patients treated with placebo.

Cardiovascular

Cardiovascular side effects have included hypotensive crisis or shock.

There has been one case report of hypotensive crisis or shock, which resolved and did not reoccur with repeated treatment.

Musculoskeletal

Pseudosepsis has been characterized as severe joint inflammation with pain and effusion occurring 24 to 72 hours after injection and it may be more likely to occur after the second or third injection or with repeated courses. Nonsteroidal anti-inflammatory drugs, intra-articular steroids, and/or arthrocentesis are often required to treat pseudosepsis.

In a pivotal clinical study 1.2% (2/164) patients treated with sodium hyaluronate (the active ingredient contained in Supartz) vs. 1.8% (3/164) patients treated with placebo were reported to have a positive bacterial culture of effusion aspirated from the treated knee. Only 1 of the placebo-treated patients required hospitalization for presumptive treatment for septic arthritis. The remaining 4 patients did not show clinical or subsequent signs of infection.

Musculoskeletal side effects have included knee swelling/effusion and pseudosepsis.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.